Antibody levels against α-galactosyl epitopes in sera of patients with squamous intraepithelial lesions and early invasive cervical carcinoma

Gynecologic Oncology

Volumn 64, Issue 2, 1997, Pages 207-212

  Tremont Lukats, Ivo W ^a   Avila, José L ^b   Hernández, Dimas ^c   Vásquez, Jesús ^a   Teixeira, Gilda M ^a   Rojas, Miguel ^b  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^b INSTITUTO DE BIOMEDICINA   (Venezuela)

^c Hospital Vargas de Caracas   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SEROLOGY; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

EID: 0031080893     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.4558     Document Type: Article

References (27)

1. 1. Galili U, Rachmilewitz EA, Peleg A, Flechner IA: A unique natural human antibody with anti-α-galactosyl specificity. J Exp Med 160:1519-1531, 1984
2. 2. Avila JL, Rojas M, Velásquez-Avila G: Characterization of a natural human antibody with antigalactosyl(α1 → 2)galactose specificity that is present at high titers in chronic Trypanosoma cruzi infection. Am J Trop Med Hyg 47:413-421, 1992
3. 3. Larsen RD, Rivera-Marrero CA, Ernst LK, Cummings RD, Lowe JB: Frameshift and nonsense mutations in a human genomic sequence homologous to a murine UDP-Gal: β-D-Gal(1,4)-D-GlcNAc α(1,3)-galactosyltransferase cDNA. J Biol Chem 265:7055-7061, 1990
4. 4. Galili U, Swanson K: Gene sequences suggest inactivation of α-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys. Proc Natl Acad Sci USA 88:7401-7404, 1991
5. 5. Hamadeh RM, Jarvis GA, Galili U, Mandrell RE, Zhou P, Grifiss JM: Human natural anti-Gal regulates alternative complement activation on bacterial surfaces. J Clin Invest 89:1223-1235, 1992
6. 6. Avila JL, Rojas M, Towbin H: Serological activity against galactosyl-α(1-3)galactose in sera from patients with several Kinetoplastida infections. J Clin Microbiol 26:126-132, 1988
7. 7. Galili U: Abnormal expression of α-galactosyl antibodies in man: A trigger for autoimmune processes? Lancet 2:358-361, 1989
8. 8. Galili U, Gregory CR, Morris RE: Contribution of anti-Gal to primate and human IgG binding to porcine endothelial cells. Transplantation 60:210-213, 1995
9. 9. Towbin H, Rosenfelder G, Wieslander J, Avila JL, Rojas M, Szarfman A: Circulating antibodies to mouse laminin in Chagas' disease, American cutaneous leishmaniasis and normal individuals recognize terminal galactosyl(αl → 3)galactose epitopes. J Exp Med 166:419-432, 1987
10. 10. Kawata M, Sekiya S, Takamizawa H, Muramatsu T, Okumura K: Molecular properties of F9 embryoglycan recognized by a unique antibody in sera from patients with germ cell tumors. Cancer Res 47:2288-2294, 1987
11. 11. Castronovo V, Colin C, Parent B, Foidart JM, Lambotte R, Mahieu P: Possible role of human natural anti-Gal antibodies in the natural antitumor defense system. J Natl Cancer Inst 81:212-216, 1989
12. 12. Tremont-Lukats IW, Arbona-Haddad EI, Avila JL, Hernández D, Rojas M, Martínez A: Immunoreactivity against Gal(α1 → 2)Gal and Gal(α1 → 3)Gal epitopes in sera from patients with cancer. J Tumor Marker Oncol 10:55-63, 1995
13. 13. Kiviat NB, Koutsky LA, Critchlow CW, Lorincz AT, Cullen AP, Brockway J, Holmes KK: Prevalence and cytological manifestations of human papilloma virus (HPV) types 6, 11, 16, 18, 31, 33, 35, 42, 43, 44, 51, 52, and 56 among 500 consecutive women. Int J Gynecol Pathol 11:197-203, 1992
14. 14. Anderson MC: Premalignant and malignant lesions of the cervix, in Fox H, Wells M (ed): Haines & Taylor Obstetrical and Gynaecological Pathology. London, Churchill-Livingstone, 1995, pp 273-321
15. 15. Capote L: Epidemiología del Cáncer en Venezuela, in: Acquatella G (ed): Manual de Quimioterapia Antineoplásica, 3rd ed, Caracas, 1995, pp 14-25
16. 16. Hatch K: Preinvasive cervical neoplasia. Semin Oncol 21:12-16, 1994
17. 17. Benda JA: Pathology of cervical carcinoma and its prognostic implications. Semin Oncol 21:3-11, 1994
18. 18. Syrjänen K, Kataja V, Yliskoski M, Chang F, Syrjänen S, Saarikoski S: Natural history of cervical human papillomavirus lesions do not substantiate the biologic relevance of the Bethesda System. Obstet Gynecol 79:675-682, 1992
19. 19. Gabrielli A, Candela M, Pisani E, Hermann K, Wieslander J, Danieli G, Krieg T: Antibodies against terminal galactosyl(α1-3)galactose epitopes in systemic sclerosis (scleroderma). Clin Exp Rheumatol 10:31-36, 1992
20. 20. Wilder J, Avila JL, Hernández D, Pérez-Torrealba JR, Rojas M, Moreno L: Antigalactosyl α1-3 galactose (anti-Gal) and breast cancer. J Tumor Marker Oncol 7:25-32, 1992
21. 21. Wieslander J, Mansson O, Kallin E, Gabrielli A, Nowak H, Timpl R: Specificity of human antibodies against gal(α1 → 3)gal epitopes and distinction from natural antibodies reacting with gal(α1 → 2)gal or gal(α1 → 4)gal. Glycoconjugate J 7:85-100, 1990
22. 22. Avila JL, Rojas M, Rodas A, Convit J: Parasitic oligosaccharide residues recognized by patients with mucocutaneous and localized cutaneous leishmaniasis. Am J Trop Med Hyg 47:284-290, 1992
23. 23. Rother RP, Fodor WL, Springhorn JP, Birks CW, Setter E, Sandrin MS, Squinto SP, Rollins SA: A novel mechanism of retrovirus inactivation in human serum mediated by anti-α-galactosyl natural antibody. J Exp Med 182:1345-1355, 1995
24. 24. Gorelik E, Duty L, Anaraki F, Galili U: Alterations of cell surface carbohydrates and inhibition of metastatic property of murine melanomas by α1,3 galactosyltransferase transfection. Cancer Res 55:4168-4173, 1995
25. 25. Hamadeh RM, Galili U, Zhou P, Grifiss JM: Anti-α-galactosyl immunoglobulin A (IgA), IgG, and IgM in human secretions. Clin Diagn Lab Immunol 2:125-131, 1995
26. 26. Edwards RP, Pitts A, Crowley-Nowick P, Partridge EE, Gore H, Mestecky J: Immunoglobulin-containing plasma cells recruited to cervical neoplasia. Obstet Gynecol 87:520-526, 1996
27. 27. Kiviat NB, Koutsky LA: Do our current cervical cancer control strategies still make sense? (Editorial). J Natl Cancer Inst 88:317-318, 1996